Health Care • Medical/Dental Instruments
$141.39 ▲ +2.41
(+1.73%)
MKT CAP: $5.99B • VOL: 838.0K
52W L $100 52W H $145
TFX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.99B | $1.70B | $1.71B |
| YoY Revenue Growth % | +17.2% | -0.8% | — |
| Gross Profit | $1.12B | $1.04B | $753.5M |
| Gross Margin % | 56.2% | 61.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $118.4M | $103.7M | $258.7M |
| Operating Margin % | 5.9% | 6.1% | 15.1% |
| Net Income (GAAP) | -$905.6M | $70.2M | $357.6M |
| EBITDA (Normalized) | $194.6M | $176.0M | $320.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.01B | $78.6M | $400.5M |
| Capital Expenditures (CapEx) | $95.2M | $90.4M | $77.1M |
| Free Cash Flow (FCF) | -$1.11B | -$11.9M | $323.4M |
| FCF Margin % | -55.7% | -0.7% | 18.9% |
| Return on Invested Capital (ROIC %) | 1.8% | 1.5% | 10.3% |
| Cash & Short-Term Equivalents | $378.6M | $247.9M | $362.5M |
| Total Debt (Short + Long Term) | $2.54B | $1.56B | $771.0M |
| Total Stockholders' Equity | $3.12B | $4.28B | $1.58B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TFX.